Cell Therapies and Gene Therapies
Bayer is committed to become a leader in this field developing a portfolio of cell therapies and gene therapies to provide new treatment options for patients who urgently need them.
By targeting diseases at the genetic and cellular level, Cell Therapies as well as Gene Therapies (CGTs) offer an opportunity to provide treatments that could prevent, halt or even reverse individual conditions.
By translating the promise of CGTs into potential therapeutic innovations, we aim to advance the development of treatments that could provide long-term benefits for patients with unmet needs.
Learn about our pipeline
Cell Therapy
Cell Therapy involves replacing cells lost or damaged by disease, so called cell replacement therapies. They have the potential to stop or even reverse disease progression. Bayer entered the field of cell therapy by acquiring BlueRock Therapeutics in 2019.
Gene Therapy
Gene Therapy involves delivering genetic material into a patient’s cells to address the causes of disease. There are different ways that gene therapy may potentially work to help people living with a disease, including: introducing an active copy of a gene into the body to help treat a disease, turning off a “bad” gene that is causing disease or replacing a bad gene with a healthy copy of the gene. In 2020, Bayer strengthened its commitment to the field of gene therapies by acquiring AskBio Inc.